Details for Patent: 12,478,696

« Back to Dashboard

Which drugs does patent 12,478,696 protect, and when does it expire?

Patent 12,478,696 protects AMBELVIST and is included in one NDA.

This patent has sixty-three patent family members in forty-three countries.

Summary for Patent: 12,478,696

Title:	Gadolinium chelate compounds for use in magnetic resonance imaging
Abstract:	An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.
Inventor(s):	Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
Assignee:	Bayer Pharma AG
Application Number:	US18/983,625
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 12,478,696

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-001	Jun 12, 2026		RX	Yes	Yes	12,478,696			Y
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-002	Jun 12, 2026		RX	Yes	Yes	12,478,696			Y
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-003	Jun 12, 2026		RX	Yes	Yes	12,478,696			Y
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-004	Jun 12, 2026		RX	Yes	Yes	12,478,696			Y
Bayer Healthcare	AMBELVIST	gadoquatrane	SOLUTION;INTRAVENOUS	219627-005	Jun 12, 2026		RX	Yes	Yes	12,478,696			Y

International Family Members for US Patent 12,478,696

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	104897
Australia	2016272602
Brazil	112017026135
Canada	2987993
Chile	2017003083